HydraFacial LLC v. Bio-Infusions USA — ITC Violation Found in 292 Days
HydraFacial LLC brought an ITC Section 337 infringement action against Bio-Infusions USA Inc. over two patents covering skin treatment devices and methods. After 292 days before ALJ Doris Johnson Hines, the Commission found a violation — a judgment on the merits for the patent holder that typically triggers an exclusion order barring the infringing goods from US import.
HydraFacial secures ITC violation finding against skin-device importer
Filed on 8 August 2024 before the United States International Trade Commission, Investigation No. 337-TA-1417 saw HydraFacial LLC — formerly Edge Systems LLC — assert two patents, US11446477B2 and US12053607B2, against Bio-Infusions USA Inc. Both patents cover devices and methods for treating skin, a technology domain closely associated with HydraFacial’s flagship hydradermabrasion platform. The ITC is the preferred forum when a patent holder seeks to block importation of competing goods rather than pursue damages in district court.
The investigation concluded on 27 May 2025 with a violation finding — a judgment on the merits in favour of HydraFacial. At the ITC, a violation finding under Section 337 typically precedes a remedial order, most commonly a Limited Exclusion Order (LEO) prohibiting the importation of the offending Bio-Infusions products into the United States. The public record does not disclose whether a consent order, bond, or interim relief was separately negotiated.
At 292 days, the investigation resolved somewhat faster than the ITC’s historical median, consistent with cases where the respondent’s participation may have been limited — noting that no defendant agents or law firms are recorded in the public docket. The absence of recorded defence counsel may suggest Bio-Infusions did not mount a substantive defence, which could explain both the speed of resolution and the strength of the merits outcome for HydraFacial. What follows from the violation finding — including the scope of any exclusion order — depends on the Commission’s final remedy determination.
Filing to Judgment on the merits for Plaintiff in 292 days
292 days — faster than the ITC’s typical 16-month investigation average
ITC violation found: what the merits ruling means for both parties
Section 337 violation finding — what it means
A Section 337 violation finding by the ITC means the Administrative Law Judge and/or Commission determined that the respondent’s imported goods infringe the asserted patents. This is a full merits determination — not a procedural default. It differs from a district court judgment in that the primary remedy is exclusionary: the Commission typically issues a Limited Exclusion Order blocking importation of the offending goods rather than awarding monetary damages.
Merits determinationHydraFacial gains import exclusion leverage
A violation finding positions HydraFacial to receive a Limited Exclusion Order barring Bio-Infusions’ infringing skin treatment devices from the US market. This is commercially powerful: it acts at the border, requiring US Customs and Border Protection to detain shipments without requiring HydraFacial to pursue each infringer in district court. Both asserted patents — US11446477B2 and US12053607B2 — survive the investigation with their enforceability reinforced.
Exclusion order expectedBio-Infusions faces US market exclusion
Bio-Infusions USA Inc. faces the prospect of a Limited Exclusion Order that would prohibit it from importing its skin treatment devices into the United States. The absence of recorded defence counsel in the public docket suggests the company may not have mounted a substantive defence, which typically forecloses most avenues of reversal on appeal. The respondent may seek a design-around or licensing negotiation as the primary remaining commercial options.
Import ban riskITC win raises barrier for skin-device importers
HydraFacial’s ITC victory signals active enforcement of its hydradermabrasion patent portfolio against importers. Competitors and distributors importing functionally similar skin treatment devices should treat US11446477B2 and US12053607B2 as live enforcement risks. An ITC exclusion order — once issued — is brand-specific and may not capture all third-party importers, but the precedent of a merits violation finding strengthens HydraFacial’s leverage in any parallel or future enforcement actions.
Enforcement precedent setFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | HydraFacial LLC f/k/a Edge Systems LLC | Company | Skin treatment device manufacturer — holder of US11446477B2 and US12053607B2Search in Eureka ↗ |
| Defendant | Bio-Infusions USA Inc. | Company | Bio-Infusions USA Inc. — US importer of skin treatment devices and methodsSearch in Eureka ↗ |
| Plaintiff counsel | Stephanie Roberts | Attorney | Counsel for HydraFacial LLC f/k/a Edge Systems LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing HydraFacial LLC f/k/a Edge Systems LLCSearch in Eureka ↗ |
| Presiding judge | Judge Doris Johnson Hines | Judge | United States International Trade CommissionSearch in Eureka ↗ |
Official order — verbatim text
The recorded verdict — ‘Participant Disposition: Violation Found’ with a basis of ‘Judgment on the merits for Plaintiff’ — is an unambiguous merits determination in HydraFacial’s favour. This is not a default judgment in the procedural sense; it reflects the ITC’s assessment that the imported skin treatment devices infringed the asserted claims of US11446477B2 and US12053607B2. The phrasing ‘judgment on the merits’ signals that the Commission reached the substance of the infringement claims, which carries weight in any subsequent district court or parallel enforcement proceeding.
US11446477B2 & US12053607B2 — skin treatment devices and methods
US11446477B2 (application no. US16/517268) and US12053607B2 (application no. US18/487916) both protect technology within the domain of devices and methods for treating skin. HydraFacial — formerly Edge Systems LLC — is the commercial originator of the hydradermabrasion category, and these patents are consistent with the company’s strategy of layering device architecture and method claims across successive application filings to extend protection across the product lifecycle. The continuation-style filing pattern suggested by the application numbers indicates a maturing, deliberately constructed patent family.
Strategically, both patents represent front-line enforcement assets in a market where Chinese and other international manufacturers have increasingly produced lower-cost alternatives to HydraFacial’s flagship system. The ITC violation finding — without any recorded validity challenge — means neither patent’s claims were successfully contested in this proceeding, reinforcing their value as deterrents. Competitors developing or importing multi-modal skin treatment platforms should treat both patents as high-priority FTO targets before entering the US market.
Should you run an FTO against US11446477B2 and US12053607B2?
Any company importing, distributing, or commercialising skin treatment devices in the United States — particularly hydradermabrasion, multi-modal facial platforms, or fluid-delivery aesthetics systems — should conduct a formal freedom-to-operate analysis against both HydraFacial patents. The ITC violation finding demonstrates active enforcement willingness, and both patents emerged from this investigation without a recorded validity challenge, making them higher-risk obstacles for market entry.
PatSnap Eureka’s FTO Search Agent can map your device’s technical features against the claim scope of US11446477B2 and US12053607B2, identify prosecution history estoppel limits, and surface related family members that may present additional risk. For R&D and product teams designing next-generation aesthetics devices, Eureka’s landscape analysis can identify design-around pathways before your product reaches the US border.
Run a freedom-to-operate analysis on US11446477B2 to assess your product’s exposure
Run FTO in Eureka →Similar ITC Section 337 cases in skin treatment and aesthetics devices
Explore Section 337 ITC investigations involving skin treatment devices, medical aesthetics platforms, and beauty technology patents before the USITC.
What this case signals for the skin treatment device IP landscape
HydraFacial’s ITC win against an importer sets a clear enforcement template for the medical aesthetics device sector.
ITC is the enforcement forum of choice for device importers
By filing at the ITC rather than district court, HydraFacial bypassed the need to prove damages and secured a faster, more commercially decisive remedy — border exclusion. Companies in the aesthetics device market importing competing hardware should assess whether their products clear the asserted patent claims before entering the US market.
Uncontested ITC proceedings typically resolve faster and more decisively
The absence of recorded defence counsel for Bio-Infusions is consistent with a case where the respondent did not mount a full defence. ITC investigations where respondents default or participate minimally tend to resolve more quickly and result in stronger violation findings, as evidentiary challenges and claim construction contests are not raised to complicate the record.
HydraFacial v Bio-Infusions — key questions answered
The ITC found a Section 337 violation on the merits in favour of HydraFacial LLC. The investigation, filed 8 August 2024 and closed 27 May 2025, resulted in a judgment on the merits for the plaintiff. A remedial order — typically a Limited Exclusion Order — is expected to follow the violation finding.
HydraFacial asserted two patents: US11446477B2 (application no. US16/517268) and US12053607B2 (application no. US18/487916). Both patents cover devices and methods for treating skin and are part of HydraFacial’s hydradermabrasion and aesthetics device patent portfolio.
A violation finding exposes Bio-Infusions USA Inc. to a Limited Exclusion Order from the ITC, which would prohibit the importation of its infringing skin treatment devices into the United States. US Customs and Border Protection enforces such orders at the border. Bio-Infusions’ options are limited to appeal, licensing negotiation, or redesigning products to avoid the asserted patent claims.
The ITC provides an exclusionary remedy — import bans — rather than monetary damages, making it the preferred forum when a patent holder’s primary goal is to remove competing imported products from the US market. ITC investigations also typically resolve faster than district court litigation and do not require proof of damages, which is commercially advantageous for established market players like HydraFacial.
A Limited Exclusion Order, if issued, would apply specifically to Bio-Infusions USA Inc. However, if the Commission issues a General Exclusion Order — which requires a higher evidentiary threshold — it would bar all importers of infringing products regardless of whether they were named in the investigation. The violation finding also strengthens HydraFacial’s hand in any future enforcement against other importers of functionally similar devices.
PatSnap Eureka searches patents and litigation data to answer instantly.